MGB Biopharma is Drug Discovery in United Kingdom that focus on healthcare organizations business. Founded in 2009. They cover business area such as developer, anti-infective, antibiotic resistance, an oral formulation, specific antibacterial activity, susceptible and resistant bacteria, bacterial infection, doctor, healthcare organization, infect patient, CDAD.
2009
( 15 years old in 2024 )
Healthcare Organizations
-
Suite 1-2, Willow House
Strathclyde Business Park, Kestrel View
Bellshill ML4 3PB
Scotland, United Kingdom
Private
developeranti-infectiveantibiotic resistancean oral formulationspecific antibacterial activitysusceptible and resistant bacteriabacterial infectiondoctorhealthcare organizationinfect patientCDAD
* We use standard office opening hours in near MGB Biopharma's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
MGB Biopharma is Drug Discovery business from United Kingdom that founded in 2009 (15 years old in 2024), MGB Biopharma business is focusing on Healthcare Organizations.
MGB Biopharma headquarter office and corporate office address is located in Suite 1-2, Willow House Strathclyde Business Park, Kestrel View Bellshill ML4 3PB Scotland, United Kingdom.
MGB Biopharma was founded in United Kingdom.
In 2024, MGB Biopharma is currently focus on healthcare organizations sector.
Above is snippet of Google Trends for "healthcare organizations" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with MGB Biopharma, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
